Purpose
To define the minimal clinically important difference (MCID), substantial clinical benefit (SCB) and patient-acceptable symptomatic state (PASS) for patient-reported outcome measures (PROMs) after medial patellofemoral ligament reconstruction (MPFLR) and to investigate the role of preoperative, demographic, and intraoperative variables for predicting achievement of these thresholds.
Methods
This retrospective cohort study used a prospectively maintained database of patients undergoing primary MPFLR between August 2015 and December 2019. PROMs included the International Knee Documentation Committee (IKDC), Knee Injury and Osteoarthritis Outcome Score (KOOS), KOOS joint replacement (JR), and Kujala. Anchor-based and distribution-based methods were used to calculate the MCID, SCB, and PASS. Regression analyses were performed to identify prognosticators for achievement of clinically significant thresholds.
Results
139 patients met inclusion criteria (mean age: 21.7± 8.2 years). At 6 months, the MCID values were 8.3 (KOOS-Pain) and 8.5/13.5 (Kujala); SCB values were 1.4 (KOOS-Pain) and 43.7 (KOOS-QOL); and PASS values were 64.9 (IKDC), 83.3 (KOOS-Symptom), 76.8 (KOOS-Pain), 91.2 (KOOS-ADL), 47.5 (KOOS-Sport), 40.6 (KOOS-QOL), and 78.1 (KOOS-JR). At 1 year, the MCID values were 4.2 (KOOS-Pain), 7.2 (KOOS-ADL), 12.4 (KOOS-QOL) and 25.2 (KOOS-JR); SCB were 23.6 (IKDC), 4.2 (KOOS-Symptom), 19.7 (KOOS-Pain), 6.5 (KOOS-ADL), 55.0 (KOOS-Sport), 6.3 (KOOS-QOL), and 19.6/25.2 (KOOS-JR); and PASS were 65.5 (IKDC), 80.4 (KOOS-Symptom), 84.7 (KOOS-Pain), 99.3 (KOOS-ADL), 57.5 (KOOS-Sport), 53.1 (KOOS-QOL), and 76.3 (KOOS-JR). In regression analysis, greater age, body mass index, and preoperative PROMs were negative prognosticators for achieving clinically significant thresholds. Conversely, male gender increased the likelihood of achieving PASS for Kujala at 6 months and KOOS-ADL at 1 year.
Conclusions
This study established thresholds for the MCID, SCB, and PASS at 6 months and 1 year after MPFLR, providing physicians an evidence-based method to advise patients and assess outcomes with this surgery. Older patients and those with higher preoperative outcome scores are less likely to report improvement and satisfaction with MPFLR, while male patients are more likely to report some satisfaction.
Level of Evidence
Level III, retrospective cohort study (diagnosis).
Introduction
Patient-reported outcome measures (PROMs) are used in clinical research to provide snapshots of patients’ levels of pain, function, activity level, and general quality of life.
1- Puzzitiello R.N.
- Gowd A.K.
- Liu J.N.
- Agarwalla A.
- Verma N.N.
- Forsythe B.
Establishing minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after biceps tenodesis.
One limitation of PROMs is that outcomes have typically been reported in terms of statistical significance, which may not represent clinical relevance or outcomes that patients perceive as important. With a growing focus in medicine on patient-centered outcomes and defining meaningful patient-reported improvement, clinically significant outcomes are increasingly emphasized over ones solely defined by statistical significance to demonstrate clinical benefit.
1- Puzzitiello R.N.
- Gowd A.K.
- Liu J.N.
- Agarwalla A.
- Verma N.N.
- Forsythe B.
Establishing minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after biceps tenodesis.
, 2- Nwachukwu B.U.
- Chang B.
- Fields K.
- et al.
Defining the “substantial clinical benefit” after arthroscopic treatment of femoroacetabular impingement.
, 3- Liu J.N.
- Gowd A.K.
- Redondo M.L.
- et al.
Establishing clinically significant outcomes after meniscal allograft transplantation.
Three metrics for clinical significance have been developed to aid in the understanding of outcome scores at the individual patient level. These include the minimal clinically important difference (MCID), the substantial clinical benefit (SCB), and the patient-acceptable symptomatic state (PASS). The MCID is defined as the smallest clinical improvement that the patients perceive as important.
2- Nwachukwu B.U.
- Chang B.
- Fields K.
- et al.
Defining the “substantial clinical benefit” after arthroscopic treatment of femoroacetabular impingement.
,3- Liu J.N.
- Gowd A.K.
- Redondo M.L.
- et al.
Establishing clinically significant outcomes after meniscal allograft transplantation.
The SCB establishes a threshold that patients determine to be a considerable improvement.
2- Nwachukwu B.U.
- Chang B.
- Fields K.
- et al.
Defining the “substantial clinical benefit” after arthroscopic treatment of femoroacetabular impingement.
,3- Liu J.N.
- Gowd A.K.
- Redondo M.L.
- et al.
Establishing clinically significant outcomes after meniscal allograft transplantation.
Lastly, the PASS represents the postoperative outcome score associated with achieving patient satisfaction.
3- Liu J.N.
- Gowd A.K.
- Redondo M.L.
- et al.
Establishing clinically significant outcomes after meniscal allograft transplantation.
,4- Cvetanovich G.L.
- Gowd A.K.
- Liu J.N.
- et al.
Establishing clinically significant outcome after arthroscopic rotator cuff repair.
These measures represent a stratification of postoperative outcomes in which MCID represents a minimal improvement, SCB represents optimal improvement, and PASS represents patient satisfaction with their outcome.
4- Cvetanovich G.L.
- Gowd A.K.
- Liu J.N.
- et al.
Establishing clinically significant outcome after arthroscopic rotator cuff repair.
Defining these values for specific procedures gives physicians a reliable, evidence-based method to measure and track clinical improvements postoperatively, as well as to help guide clinical decision making.
3- Liu J.N.
- Gowd A.K.
- Redondo M.L.
- et al.
Establishing clinically significant outcomes after meniscal allograft transplantation.
The medial patellofemoral ligament (MPFL) is the primary restraint against lateral translation of the patella and is often injured in patellar dislocations.
5- Reagan J.
- Kullar R.
- Burks R.
MPFL reconstruction: Technique and results.
, 6- Mackay N.D.
- Smith N.A.
- Parsons N.
- Spalding T.
- Thompson P.
- Sprowson A.P.
Medial patellofemoral ligament reconstruction for patellar dislocation.
, 7- Lee D.
- Park Y.
- Song S.
- Hwang S.
- Park J.
- Kang D.
Which technique is better for treating patellar dislocation? A systematic review and meta-analysis.
Initial treatment for patellar instability and/or subluxation often includes conservative management, consisting of physical therapy and bracing of the knee joint. Recurrent instability often requires surgical intervention, and MPFL reconstruction has become an increasingly popular treatment option.
7- Lee D.
- Park Y.
- Song S.
- Hwang S.
- Park J.
- Kang D.
Which technique is better for treating patellar dislocation? A systematic review and meta-analysis.
, 8- Csintalan R.P.
- Latt L.D.
- Fornalski S.
- Raiszadeh K.
- Inacio M.C.
- Fithian D.C.
Medial patellofemoral ligament (MPFL) reconstruction for the treatment of patellofemoral instability.
, 9- Erickson B.J.
- Mascarenhas R.
- Sayegh E.T.
- et al.
Does operative treatment of first-time patellar dislocations lead to increased patellofemoral stability? A systematic review of overlapping meta-analyses.
However, the thresholds for MCID, SCB, and PASS for MPFL reconstruction have yet to be defined in the literature. Appropriately defining these values can provide better understanding of PROMs and clinical success after MPFL reconstruction. Therefore, the goal of this study was to define the MCID, SCB, and PASS for PROMs after MPFLR and to investigate the role of preoperative, demographic, and intraoperative variables for predicting achievement of these thresholds. The hypothesis of this study was that there are net changes and absolute outcome score values that represent the MCID, SCB, and PASS that can accurately predict patient perception of improvement and satisfaction, and, additionally, that there are patient variables that can be used to predict achievement of these thresholds.
Discussion
The present study established values for the MCID, SCB, and PASS at 6 months and 1 year postoperatively for patients undergoing primary MPFL reconstruction with respect to commonly administered knee and patellofemoral outcome measures, including IKDC, Kujala, KOOS JR, and KOOS subscales (Pain, Symptoms, ADL, Sport, and QOL) (
Table 7). We chose the 6-month follow-up over a later time point to align with the 4-to-6-month return to sport timetable that is commonly used for rehabilitation following MPFL reconstruction, according to previously published protocols.
10- Fisher B.
- Nyland J.
- Brand E.
- Curtin B.
Medial patellofemoral ligament reconstruction for recurrent patellar dislocation: A systematic review including rehabilitation and return-to-sports efficacy.
Additionally, earlier timepoints have been previously shown to be more useful for calculating the MCID using the anchor-based method, because the relatively smaller percentage of patients falling into the “no change” group at later time points lends a negative influence on the power of the calculations.
3- Liu J.N.
- Gowd A.K.
- Redondo M.L.
- et al.
Establishing clinically significant outcomes after meniscal allograft transplantation.
,23- Kukkonen J.
- Kauko T.
- Vahlberg T.
- Joukainen A.
- Äärimaa V.
Investigating minimal clinically important difference for Constant score in patients undergoing rotator cuff surgery.
Finally, because of the relative paucity of the literature on the topics of postoperative outcomes and recovery timetables after MPFL reconstruction, we also wanted to allow for analysis of both 6-month and 1-year postoperative data to help fill these gaps in the literature.
The three commonly accepted strategies used to determine the MCID include “anchor-based”, “distribution-based” or “opinion-based” methodologies.
16A point of minimal important difference (MID): A critique of terminology and methods.
,24- Tashjian R.
- Deloach J.
- Green A.
- Porucznik C.
- Powell A.
Minimal clinically important differences in ASES and simple shoulder test scores after nonoperative treatment of rotator cuff disease.
The United States Food and Drug Administration’s (FDA) final guidelines to industry when evaluating effectiveness of treatment using PROMs recommends the anchor-based approach to demonstrate treatment benefit.
25U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance.
The anchor-based approach allows for the comparison of changes in PROMs against anchor questions that assess subjective improvement in global domains such as overall symptoms or function.
16A point of minimal important difference (MID): A critique of terminology and methods.
,24- Tashjian R.
- Deloach J.
- Green A.
- Porucznik C.
- Powell A.
Minimal clinically important differences in ASES and simple shoulder test scores after nonoperative treatment of rotator cuff disease.
,26- Ward M.M.
- Guthrie L.C.
- Alba M.
Domain-specific transition questions demonstrated higher validity than global transition questions as anchors for clinically important improvement.
The distribution-based method uses statistical analysis to determine the minimal clinically significant change for a given PROM, but has only been validated for use with calculating MCID.
1- Puzzitiello R.N.
- Gowd A.K.
- Liu J.N.
- Agarwalla A.
- Verma N.N.
- Forsythe B.
Establishing minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after biceps tenodesis.
,21- Norman G.R.
- Sloan J.A.
- Wyrwich K.W.
Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation.
In the present study, anchor-based and distribution-based methods were both used to determine MCID to enhance predictive power, and only the anchor-based method was used to determine SCB and PASS. Although some studies have argued for the use of both anchor- and distribution-based methods to determine MCID,
1- Puzzitiello R.N.
- Gowd A.K.
- Liu J.N.
- Agarwalla A.
- Verma N.N.
- Forsythe B.
Establishing minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after biceps tenodesis.
,27- Crosby R.D.
- Kolotkin R.L.
- Williams G.R.
Defining clinically meaningful change in health-related quality of life.
one drawback is the difficultly in explaining discrepancies that may arise. Several inconsistencies were observed in the current study, including the MCID and SCB for multiple PROMs, which may be attributed to the low predictive power of these values, as evidenced by their unacceptable AUCs. In these cases, the distribution-based scores were used to define MCID, as the low AUCs suggested the anchor-based values were unreliable. By minimizing the use of thresholds that have unacceptable AUCs, we were able to maximize the predictive power of these models and reduce potential bias.
Using the calculated threshold values, we found several factors associated with failing to achieve these clinically significant outcomes following primary MPFL reconstruction, including advanced age at time of surgery, higher preoperative PRO scores, and higher BMI. Conversely, we found that male gender was associated with a greater likelihood of achieving PASS for Kujala at 6 months, and KOOS Symptom and ADL at 1 year. These threshold values are important in providing physicians and patients with benchmarks for postoperative recovery as well as insight into the changes in PROM scores necessary to achieve improvements after MPFL reconstruction that are significant and acceptable to the patient.
The use of MPFL reconstruction to treat recurrent patellar instability has gained much popularity in recent years, owing to its effectiveness in restoring the medial restraining forces of the patella
6- Mackay N.D.
- Smith N.A.
- Parsons N.
- Spalding T.
- Thompson P.
- Sprowson A.P.
Medial patellofemoral ligament reconstruction for patellar dislocation.
,7- Lee D.
- Park Y.
- Song S.
- Hwang S.
- Park J.
- Kang D.
Which technique is better for treating patellar dislocation? A systematic review and meta-analysis.
and positive clinical outcomes.
28- Schneider D.K.
- Grawe B.
- Magnussen R.A.
- et al.
Outcomes after isolated medial patellofemoral ligament reconstruction for the treatment of recurrent lateral patellar dislocations.
,29- Sappey-Marinier E.
- Sonnery-Cottet B.
- O’Loughlin P.
- et al.
Clinical outcomes and predictive factors for failure with isolated MPFL reconstruction for recurrent patellar instability: A series of 211 reconstructions with a minimum follow-up of 3 years.
A 2016 systematic review and meta-analysis of 14 studies reported an average postoperative Kujala score of 85.8 with an 84.1% return to sport rate following isolated MPFL reconstruction in the setting of chronic patellar instability, as well as low incidence of recurrent instability, postoperative apprehension, and revision surgery in the short-term.
28- Schneider D.K.
- Grawe B.
- Magnussen R.A.
- et al.
Outcomes after isolated medial patellofemoral ligament reconstruction for the treatment of recurrent lateral patellar dislocations.
Sappey-Marinier et al
29- Sappey-Marinier E.
- Sonnery-Cottet B.
- O’Loughlin P.
- et al.
Clinical outcomes and predictive factors for failure with isolated MPFL reconstruction for recurrent patellar instability: A series of 211 reconstructions with a minimum follow-up of 3 years.
reported a similar improvement in Kujala following isolated MPFL reconstruction, with patients improving from an average score of 56.1 preoperatively to 88.8 postoperatively. These authors also found that over 84% of patients returned to sport at the same level of performance. In the current study looking at MPFL reconstructions performed in isolation and with minor concomitant procedures, we found that Kujala improved from a baseline of 57.8 to 82.8 at 6 months and to 86.5 at 1 year postoperatively. Overall, we found that the change from baseline improved for all PROMs from 6 months to 1 year. This improvement aligns with the 4-to-6-month recovery timetable previously published,
10- Fisher B.
- Nyland J.
- Brand E.
- Curtin B.
Medial patellofemoral ligament reconstruction for recurrent patellar dislocation: A systematic review including rehabilitation and return-to-sports efficacy.
and continues up to 1 year after surgery. Outcomes beyond 1 year are beyond the scope of the current study, and further investigation using longer follow-up timeframes is warranted.
Within MPFL reconstruction surgery, the importance of preoperative and demographic variables associated with postoperative outcomes is well recognized.
29- Sappey-Marinier E.
- Sonnery-Cottet B.
- O’Loughlin P.
- et al.
Clinical outcomes and predictive factors for failure with isolated MPFL reconstruction for recurrent patellar instability: A series of 211 reconstructions with a minimum follow-up of 3 years.
, 30- Hiemstra L.A.
- Kerslake S.
Age at time of surgery but not sex is related to outcomes after medial patellofemoral ligament reconstruction.
, 31- Nwachukwu B.U.
- Fields K.
- Chang B.
- Nawabi D.H.
- Kelly B.T.
- Ranawat A.S.
Preoperative outcome scores are predictive of achieving the minimal clinically important difference after arthroscopic treatment of femoroacetabular impingement.
, 32- Gowd A.K.
- Lalehzarian S.P.
- Liu J.N.
- et al.
Factors associated with clinically significant patient-reported outcomes after primary arthroscopic partial meniscectomy.
In our study, we found that older age at time of surgery was associated with a decline in postoperative outcomes, carrying a reduced odds ratio of achieving MCID, SCB, and PASS for multiple PROMs at 6 months. We also found that higher BMI at the time of surgery exerted a negative influence on achieving PASS for IKDC at 1 year. These results corroborate previous literature highlighting the negative influence of age on postoperative outcomes.
30- Hiemstra L.A.
- Kerslake S.
Age at time of surgery but not sex is related to outcomes after medial patellofemoral ligament reconstruction.
Interestingly, however, we found that male sex positively influenced the odds of achieving PASS for Kujala at 6 months, and for KOOS Symptom and ADL at 1 year, which contradicts prior studies that found sex to be noninfluential on postoperative outcomes.
30- Hiemstra L.A.
- Kerslake S.
Age at time of surgery but not sex is related to outcomes after medial patellofemoral ligament reconstruction.
Lastly, we found that higher preoperative scores were negative prognosticators for achieving MCID and SCB but slightly positively influenced the achievement of PASS for KOOS QOL at 6 months, which corroborates an existing trend in the literature.
31- Nwachukwu B.U.
- Fields K.
- Chang B.
- Nawabi D.H.
- Kelly B.T.
- Ranawat A.S.
Preoperative outcome scores are predictive of achieving the minimal clinically important difference after arthroscopic treatment of femoroacetabular impingement.
, 32- Gowd A.K.
- Lalehzarian S.P.
- Liu J.N.
- et al.
Factors associated with clinically significant patient-reported outcomes after primary arthroscopic partial meniscectomy.
, 33- Cvetanovich G.L.
- Weber A.E.
- Kuhns B.D.
- et al.
Hip arthroscopic surgery for femoroacetabular impingement with capsular management: Factors associated with achieving clinically significant outcomes.
, 34- Nwachukwu B.U.
- Chang B.
- Voleti P.B.
- et al.
Preoperative short form health survey score is predictive of return to play and minimal clinically important difference at a minimum 2-year follow-up after anterior cruciate ligament reconstruction.
This is fairly intuitive because patients with greater symptoms and impairment before surgery have more room for improvement and, thus, are likely to achieve a greater increase in their outcome scores. On the other hand, PASS represents postoperative scores rather than a change from baseline, which means patients with higher preoperative scores are already closer to achieving this threshold. The propensity for patients with greater symptoms and impairment to report improvement is particularly important and should be emphasized during clinical decision making and preoperative counseling.
Although all PROMs improved from 6 months to 1 year, this study found a relative decrease in the MCID thresholds for IKDC, Kujala (vs symptom), and KOOS Symptom, Pain, ADL, and Sport; a relative decrease in the SCB threshold for KOOS Symptom, ADL, QOL, and KOOS JR (vs. pain); and a relative decrease in the PASS threshold for KOOS Symptom, Kujala, and KOOS JR over the same time period. We also found that the MCID threshold for Kujala (vs symptom) at 6 months and KOOS JR (vs ADL) at 1 year were equivalent to the SCB threshold. Additionally, the SCB thresholds were found to be lower than those for MCID for KOOS Pain at 6 months, as well as KOOS Symptom, ADL, and QOL at 1 year. These discrepancies are likely attributable to a lower quantity of patient data available for analysis at 1 year, as well as for patients categorized into the “minimal change” group. One difficulty that arose in our calculations was the significant skewedness of patients failing into the “substantial improvement” category compared with the “no change” and “minimal improvement” categories, which may account for the relatively lower AUC values found for MCID. On the extreme end, zero patients fell into the “no change” groups for IKDC and Kujala (vs function) at 6 months, thus precluding any anchor-based analysis of those thresholds. Furthermore, we observed for many of the lowest AUC values that the average scores for the “no change” group were greater than the average values for the corresponding “minimal change” group, which is fairly intuitive because the ROC/AUC analysis evaluates how well the model distinguishes between the two groups and this inverse trend indicates a poor model. The relatively higher average values in these “no change” group were likely affected by the lower quantity of patient data available for analysis and may not reflect a true average. It remains to be seen if a larger sample size would help elucidate these trends, and further investigation is warranted.
Limitations
This study is not without inherent limitations. First, our study was underpowered because our patient follow-up at 1 year was 40%. This limited our sample size and increased the risk of a selection bias in our cohort, as well as potentially reduced the generalizability and internal validity of these results. Second, while several commonly used PROMs related to knee symptoms, pain, and function were analyzed in this study, PROMs specific to patellar instability, such as the Banff Patella Instability Instrument and the Norwich Patellar Instability Score, were not included and, thus, limits the utility of these results for patients undergoing MPFL reconstruction. In our practice, these PROMs are not routinely administered, so these data were not available for analysis and additional inquiry into these PROMs and their outcome scores is needed. Third, the inclusion of minor concomitant procedures introduces a potential confounding variable. This effect was minimized by the exclusion of all major concomitant procedures that had the ability to alter surgical techniques or rehabilitation protocols. Given the relatively minor concomitant procedures included in this study, isolated and combination MPFL reconstructions were deemed to be sufficiently comparable for analysis. Fourth, the fact that 20.9% of our patient cohort had prior surgery on the index knee represents another potential confounding variable; however, the heterogeneity of these prior surgeries and the relatively low numbers of patients in each category precluded proper analysis of their effects. Further investigation with a larger patient population is needed to ascertain any influence that these variables and limitations may have. Lastly, this study was a retrospective review of prospectively collected data. As a result, we were unable to introduce an anchor question for anchor-based sensitivity analysis and, thus, were unable to perform any sensitivity analyses around our threshold values. The MCID, SCB, and PASS were calculated using a combination of anchor- and distribution-based methods,
34- Nwachukwu B.U.
- Chang B.
- Voleti P.B.
- et al.
Preoperative short form health survey score is predictive of return to play and minimal clinically important difference at a minimum 2-year follow-up after anterior cruciate ligament reconstruction.
,35- Jaeschke R.
- Singer J.
- Guyatt G.H.
Measurement of health status: Ascertaining the minimal clinically important difference.
and neither is without its pitfalls nor do either demonstrate consistent superiority. Ideally, the disease under investigation and characteristics of the data should drive the determination of the methodologies used.
34- Nwachukwu B.U.
- Chang B.
- Voleti P.B.
- et al.
Preoperative short form health survey score is predictive of return to play and minimal clinically important difference at a minimum 2-year follow-up after anterior cruciate ligament reconstruction.
Conclusion
This study established values for the MCID, SCB, and PASS at 6 months and 1 year after MPFLR, providing physicians an evidence-based method to advise patients and assess outcomes regarding this surgery. Older patients and those higher preoperative outcome scores are less likely to report improvement and satisfaction with MPFLR, while male patients are more likely to report some satisfaction.
Article info
Publication history
Published online: February 09, 2022
Accepted:
December 12,
2021
Received:
April 21,
2021
Footnotes
The authors report the following potential conflicts of interest or sources of funding: S.E.W. reports being a paid speaker for DJ Orthopaedics and has received grants from Arthrex, Inc. and Acumed. B.F. reports personal fees from Elsevier, Jace Medical, and Stryker and being a paid consultant for Stryker, outside the submitted work. A.B.Y. reports grants from Organogenesis, Vericel, and Arthrex, Inc.; personal fees from CONMED Linvatec, JRF Ortho, and Olympus; nonfinancial support from Patient IQ, Smith & Nephew, Sparta Biomedical; and stock or stock options from Patient IQ, outside the submitted work. N.V. reports receiving personal fees from Cymedica, Minivasive, Omeros, Orthospace, Stryker, and Medacta USA, Inc.; receiving royalties from Arthroscopy, Smith & Nephew, and Vindico Medical-Ortho Hyperguide; being a board or committee member of AOSSM, ASES, AANA, Knee, and SLACK, Inc., outside the submitted work. B.J.C. reports personal fees from Ossio, Regentis, and Arthrex; research support from the National Institutes of Health and Aesculap; being a paid consultant for Aesculap, Regentis, Arthrex, Acumed, and Vericel Corporation; IP royalties from Elsevier, Arthrex, and Operative Techniques in Sport Medicine; and stock or stock options from Ossio, Regentis, and Bandgrip, Inc., outside the submitted work. Full ICMJE author disclosure forms are available for this article online, as supplementary material.
Copyright
© 2022 Published by Elsevier Inc. on behalf of the Arthroscopy Association of North America